Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
JCI accreditation is recognized globally
Subscribe To Our Newsletter & Stay Updated